CN1777576A - 用于治疗代谢紊乱的化合物 - Google Patents

用于治疗代谢紊乱的化合物 Download PDF

Info

Publication number
CN1777576A
CN1777576A CNA2004800107323A CN200480010732A CN1777576A CN 1777576 A CN1777576 A CN 1777576A CN A2004800107323 A CNA2004800107323 A CN A2004800107323A CN 200480010732 A CN200480010732 A CN 200480010732A CN 1777576 A CN1777576 A CN 1777576A
Authority
CN
China
Prior art keywords
carbon atoms
formula
compound
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800107323A
Other languages
English (en)
Chinese (zh)
Inventor
科尔文·L·霍奇
罗伯特·J·考夫曼
阿尔伯特·李
沙林·夏尔马
里德·W·冯博斯特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Therapeutics Corp
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of CN1777576A publication Critical patent/CN1777576A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2004800107323A 2003-04-22 2004-04-20 用于治疗代谢紊乱的化合物 Pending CN1777576A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46455303P 2003-04-22 2003-04-22
US60/464,553 2003-04-22

Publications (1)

Publication Number Publication Date
CN1777576A true CN1777576A (zh) 2006-05-24

Family

ID=33310913

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800107323A Pending CN1777576A (zh) 2003-04-22 2004-04-20 用于治疗代谢紊乱的化合物

Country Status (8)

Country Link
US (1) US7361686B2 (enExample)
EP (1) EP1618086B1 (enExample)
JP (1) JP4697973B2 (enExample)
CN (1) CN1777576A (enExample)
AT (1) ATE450496T1 (enExample)
CA (1) CA2521589C (enExample)
DE (1) DE602004024382D1 (enExample)
WO (1) WO2004093806A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2341513C2 (ru) * 2001-06-12 2008-12-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических заболеваний
ES2530235T3 (es) * 2003-02-13 2015-02-27 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
ES2353601T3 (es) * 2003-04-15 2011-03-03 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos.
CA2522738C (en) * 2003-04-30 2011-11-08 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MXPA06001963A (es) * 2003-08-20 2006-05-31 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
WO2006127133A2 (en) * 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
EP1976510A4 (en) * 2006-01-25 2010-06-09 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
AU2007208127A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7820721B2 (en) * 2006-01-25 2010-10-26 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009525982A (ja) * 2006-02-02 2009-07-16 ウェルスタット セラピューティクス コーポレイション 代謝障害の治療のための化合物
EP1983972A4 (en) * 2006-02-13 2012-01-25 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
KR20080098615A (ko) * 2006-02-28 2008-11-11 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
WO2007117791A2 (en) * 2006-03-31 2007-10-18 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
CA2651598A1 (en) * 2006-05-18 2007-11-29 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US20100234464A1 (en) * 2006-06-09 2010-09-16 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2009091732A1 (en) * 2008-01-15 2009-07-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2009137381A1 (en) * 2008-05-05 2009-11-12 Wellstat Therapeutics Corporation Synthesis of 4-[3-(2,6-dimethylbenzyloxy)phenyl]-4-oxobutanoic acid
EP2365746B1 (en) 2008-11-04 2014-07-16 Wellstat Therapeutics Corporation Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3419952A1 (de) * 1984-05-28 1985-11-28 Bayer Ag, 5090 Leverkusen Substituierte phenoxyphenylpropionsaeure-derivate
DE3621775A1 (de) 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
AU7238394A (en) * 1993-07-29 1995-02-28 Chugai Seiyaku Kabushiki Kaisha Tricarboxylic acid derivative having squalene synthetase inhibitor activity
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
JP3880108B2 (ja) * 1994-11-02 2007-02-14 武田薬品工業株式会社 ２，４−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物
TW403748B (en) 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
JP4148681B2 (ja) * 2000-12-28 2008-09-10 武田薬品工業株式会社 アルカン酸誘導体、その製造法および用途
ATE433964T1 (de) 2000-12-28 2009-07-15 Takeda Pharmaceutical Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
RU2341513C2 (ru) * 2001-06-12 2008-12-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических заболеваний
CA2502297C (en) 2002-11-01 2011-12-13 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ES2530235T3 (es) 2003-02-13 2015-02-27 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
ES2353601T3 (es) 2003-04-15 2011-03-03 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos.
CA2522738C (en) 2003-04-30 2011-11-08 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
JP4697973B2 (ja) 2011-06-08
EP1618086A2 (en) 2006-01-25
EP1618086A4 (en) 2007-05-09
DE602004024382D1 (de) 2010-01-14
US20070105955A1 (en) 2007-05-10
US7361686B2 (en) 2008-04-22
EP1618086B1 (en) 2009-12-02
HK1083462A1 (en) 2006-07-07
WO2004093806A2 (en) 2004-11-04
ATE450496T1 (de) 2009-12-15
JP2006524252A (ja) 2006-10-26
CA2521589C (en) 2011-11-01
WO2004093806A3 (en) 2005-04-07
CA2521589A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
CN1774244A (zh) 用于治疗代谢紊乱的化合物
CN1780614A (zh) 用于治疗代谢紊乱的化合物
CN1750758A (zh) 用于治疗代谢紊乱的化合物
CN100344616C (zh) 用于治疗代谢失调的化合物
CN1311767A (zh) 治疗代谢性疾病的糖皮质激素和甲状腺激素受体的配体
CN1155586C (zh) 取代的苄基噻唑烷-2,4-二酮衍生物
CN1280574A (zh) 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
CN1069023A (zh) 用于治疗肥胖及相关状态的4-[2-(2-羟基-2-苯乙氨基)乙氧基]苯乙酸衍生物
CN1280575A (zh) 新型三环化合物和其作为药物的用途;其制备方法和包含该化合物的药物组合物
CN1281443A (zh) 双环化合物、其制备方法和包含它们的药物组合物
CN1094711A (zh) 新的环己烷亚基衍生物
CN1219929A (zh) 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物
CN1092407A (zh) 新的环乙烷亚基衍生物
CN1342147A (zh) 具有抗炎、止痛和抗血栓形成活性的硝基氧基衍生物
EP1618086B1 (en) Compounds for the treatment of metabolic disorders
CN1835743A (zh) 用于治疗代谢紊乱的化合物
CN1617854A (zh) 苯基(烷基)羧酸衍生物和二酸苯基烷基杂环衍生物及其用作具有血清葡萄糖和/或血清脂降低活性的药物的应用
JP3491635B2 (ja) ジヒドロナフタレン誘導体化合物およびその化合物を有効成分とする薬剤
CN85107496A (zh) 制备四氢化萘衍生物的方法
CN1257893C (zh) 具有优异降糖降酯活性的芳烷基氨基酸类ppar全激活剂
CN1728992A (zh) 具有降低血清葡萄糖和降低血清脂质活性的α－苯硫基羧酸和α－苯氧基羧酸的用途
EP1868595B1 (en) Compounds for the treatment of metabolic disorders
CN1596106A (zh) 三氟乙酰烷基－取代的苯基－、苯酚－和苯甲酰基衍生物在治疗和/或预防肥胖症和其并发症和/或后遗症中的应用
CN1239944A (zh) 季戊四醇的新衍生物、其制备方法和用途以及用于合成它的中间体
CN1023599C (zh) 氯苯胺衍生物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication